# Aleniglipron Phase 2 Body Composition Study

> **NCT07169942** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics** · enrollment: 71 (actual)

## Conditions studied

- Obesity, Overweight, or Chronic Weight Management

## Interventions

- **DRUG:** aleniglipron or placebo

## Key facts

- **NCT ID:** NCT07169942
- **Lead sponsor:** Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-08-15
- **Primary completion:** 2026-08
- **Final completion:** 2026-10
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2026-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07169942

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07169942, "Aleniglipron Phase 2 Body Composition Study". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07169942. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*